Evidence map›Paper›PMID 34251050›Full record

ArticleImmunology2021

Enigmatic inflammasomes - Sequel (Part 2).

Kathy Triantafilou

Open access · bronzeAbstract readEditorial
In one paragraph

Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kathy TriantafilouImmunology Catalyst, Immunology Network, Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
University Hospital of Wales · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue, we introduce the second part of our review series focusing on lesser-known enigmatic inflammasomes. This part of the collection introduces one more under-studied NLR, NLRP7, and not only its role as a regulator of inflammation in response to bacterial infections but also its non-inflammasome role in early pregnancy. In addition, the enigmatic function of extracellular ASC specks is also introduced, where extracellular ASC specks are presented as 'danger signals' to propagate inflammation. The series is concluded with an article that reviews the immunometabolic regulation of all of these lesser-known NLRs, demonstrating that metabolic regulation of inflammasome activation is central for the whole NLR family. These three reviews, together with the four articles that were published in the first part of the series in December 2020, offer new insights into the complex functions of NLRs, well beyond the well-known NLRP3. The review series as a whole provides a thought-provoking platform with some of the latest findings in the NLR field and sparks our imagination into what might be discovered in this space in the future.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBacterial InfectionsFemaleHumansInflammasomesInflammationNLR Family, Pyrin Domain-Containing 3 ProteinPregnancySignal TransductionAdaptor Proteins, Signal TransducingInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP7 protein, human

Identifiers

PMID34251050
PMCPMC8274183
OpenAlexW3180770684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.